CN113244204B - 姜烯酮a在制备和/或作为增强机体免疫力产品中的应用 - Google Patents
姜烯酮a在制备和/或作为增强机体免疫力产品中的应用 Download PDFInfo
- Publication number
- CN113244204B CN113244204B CN202110536050.1A CN202110536050A CN113244204B CN 113244204 B CN113244204 B CN 113244204B CN 202110536050 A CN202110536050 A CN 202110536050A CN 113244204 B CN113244204 B CN 113244204B
- Authority
- CN
- China
- Prior art keywords
- zingiberenone
- immunity
- enhancing
- zingiberone
- cyclophosphamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 41
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 17
- 210000000056 organ Anatomy 0.000 claims abstract description 16
- 102100033220 Xanthine oxidase Human genes 0.000 claims abstract description 14
- 108010093894 Xanthine oxidase Proteins 0.000 claims abstract description 14
- 210000000952 spleen Anatomy 0.000 claims abstract description 14
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 12
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 12
- 102000016943 Muramidase Human genes 0.000 claims abstract description 12
- 108010014251 Muramidase Proteins 0.000 claims abstract description 12
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 12
- 229960000274 lysozyme Drugs 0.000 claims abstract description 12
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 12
- 239000004325 lysozyme Substances 0.000 claims abstract description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 6
- 230000001965 increasing effect Effects 0.000 claims description 37
- 230000002992 thymic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000036737 immune function Effects 0.000 abstract description 13
- 210000001541 thymus gland Anatomy 0.000 abstract description 12
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 8
- 229930001895 zingiberene Natural products 0.000 abstract description 8
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 abstract description 7
- 230000001681 protective effect Effects 0.000 abstract description 4
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 41
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 39
- 229960004397 cyclophosphamide Drugs 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000893536 Epimedium Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001165494 Rhodiola Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 235000018905 epimedium Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- -1 zingiberene ketone Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了姜烯酮A在制备和/或作为增强机体免疫力产品中的应用。本发明研究表明,中药生姜活性成分姜烯酮A不仅能够提高白细胞介素2、免疫球蛋白、溶菌酶、黄嘌呤氧化酶的表达水平,显著改善机体的免疫功能,没有明显的副作用,而且能够增加机体的脾脏系数和胸腺系数,对免疫器官具有保护作用,说明姜烯酮A是一种能够增强机体免疫功能的中药活性成分,能够用于制备和/或作为增强机体免疫力的药物和/或保健品。
Description
技术领域
本发明涉及生物医药技术领域,具体地,涉及姜烯酮A在制备和/或作为增强机体免疫力产品中的应用。
背景技术
免疫是人体的一种生理功能,在维持人体中发挥免疫监视、防御、调控等作用。引起免疫力低下的因素有很多,例如:紧张不安、焦急等心理会给植物性神经造成不良影响,而植物性神经和内分泌系统及免疫系统有着紧密的联系;睡眠不足、身体过度疲劳也会加重植物性神经的负担,从而对内分泌系统及免疫系统带来不良影响;吃过多主食、摄入过多碳水化合物导致免疫力低下等。在快节奏、高效率的现代社会,人们常常长期处于竞争激烈、心理压力大、超负荷运行的紧张状态中,这种状况如不能及时化解,则很容易产生生理和心理的疾病。当各种因素诱发免疫系统不能正常发挥保护作用时,就会造成免疫功能低下。除此之外,越来越多的研究表明免疫功能低下与多种疾病相关,如肿瘤、代谢性疾病和炎症性疾病等。目前,关于增强免疫力的研究颇多,主要分为西药疗法、中药疗法以及食物疗法。其中,服用西药是一种快速提高免疫力的方法,比如患者通过服用胸腺肽和胸腺五肽这些免疫调节剂进行药物治疗,但是这些药物具有一定的副作用,也不宜长期服用;而通过调节饮食的方式来增强免疫力,恢复速度较慢。中药往往具有多种功效,且其对机体造成的不良反应明显低于西药。目前,已有研究表明中药具有提高免疫力的功效,例如:公布号为CN102861260A的中国专利公开了一种增强免疫力的中药,所述中药由以下重量配比的中药原料组成:红景天15~25份、龙眼肉20~30份、怀山药20~30份、西杞果5~15份、薏苡仁20~30份、葛根15~25份、丹参15~25份、党参5~10份、五味子10~15份、甘草20~30份、茶叶20~30份,该中药具有对人体具有调和营卫、补气养血、扶正祛邪,提高免疫力,增强超氧化物歧化酶活力,抑制脂质过氧化反应,防治感冒的功能;公布号为CN103169071A的中国专利公开了一种增强免疫力中草药配方,所述配方是由淫羊藿粉、红景天粉经混合制备而成,其中按重量百分比计各组分的含量为:淫羊藿粉40~70、红景天粉50~80。然而,上述中药成分复杂,增强免疫力的有效成分仍有待进一步分析与明确,且增强免疫力的功效有待提高。因此从中药中寻找能够增强机体免疫功能的活性成分,具有重要的现实意义。
发明内容
本发明的目的在于克服现有技术中存在的上述缺陷和不足,开发一种能够用于增强机体免疫功能的中药活性成分,通过探究中药生姜活性成分姜烯酮A的增强免疫力的性能,提供姜烯酮A在制备和/或作为增强机体免疫力产品中的应用。
本发明的第二个目的在于提供一种活性成分包括姜烯酮A的增强机体免疫力的产品。
本发明的上述目的是通过以下技术方案给予实现的:
本发明通过环磷酰胺诱导小鼠构建免疫功能低下动物模型,评价姜烯酮A对免疫功能低下小鼠的免疫功能恢复效果。实验分为正常对照组、环磷酰胺模型组、环磷酰胺+姜烯酮A低剂量组(5mg/kg)、环磷酰胺+姜烯酮A中剂量组(10mg/kg)、环磷酰胺+姜烯酮A高剂量组(20mg/kg)。通过对免疫功能低下小鼠血清中的炎性细胞因子及生化指标检测评价姜烯酮A对小鼠免疫功能恢复的影响。本发明研究表明,与正常对照组比较,环磷酰胺模型组小鼠的白细胞介素2、免疫球蛋白、溶菌酶、黄嘌呤氧化酶的表达水平显著降低,差异具有统计学意义(P<0.01);而给予了姜烯酮A后,与环磷酰胺模型组比较,环磷酰胺+姜烯酮A中剂量组小鼠血清中的IgG、XOD的表达水平显著增高(P<0.05),环磷酰胺+姜烯酮A高剂量组小鼠血清中的IL-2、IgG和LZM的表达水平显著增高(P<0.05),XOD的表达水平极显著增高(P<0.01)。本发明还通过计算免疫功能低下小鼠免疫器官的脏器系数来评价姜烯酮A的增强免疫力性能。本发明研究表明,与正常对照组比较,环磷酰胺模型组的脾脏系数和胸腺系数显著降低,差异具有统计学意义(P<0.01);而给予姜烯酮A后,小鼠的脾脏系数和胸腺系数随着姜烯酮A剂量的升高而增加。其中,与环磷酰胺模型组比较,环磷酰胺+姜烯酮A中剂量组的脾脏系数和胸腺系数增加明显(P<0.05),环磷酰胺+姜烯酮A高剂量组的胸腺系数增加明显(P<0.05)、脾脏系数极显著增加(P<0.01)。
上述研究结果表明,姜烯酮A具有增强免疫力的作用,因此,本发明提供了姜烯酮A在制备和/或作为增强机体免疫力产品中的应用。
具体地,姜烯酮A通过增高白细胞介素2含量增强机体免疫力。
具体地,姜烯酮A通过增高免疫球蛋白含量增强机体免疫力。
具体地,姜烯酮A通过增高溶菌酶含量增强机体免疫力。
具体地,姜烯酮A通过增高黄嘌呤氧化酶含量增强机体免疫力。
具体地,姜烯酮A通过保护机体免疫器官增强机体免疫力。
具体地,姜烯酮A通过增加脾脏系数保护机体免疫器官。
具体地,姜烯酮A通过增加胸腺系数保护机体免疫器官。
本发明还提供了一种增强免疫力的产品,其活性成分包括姜烯酮A。
优选地,上述任一所述产品为药物和/或保健品。
更优选地,所述药物和/或保健食品制成药物学上可接受的制剂普通片、咀嚼片、含片、泡腾片、分散片、口服液、饮料、颗粒剂、胶囊剂、散剂。
与现有技术相比,本发明具有以下有益效果:
本发明提供了姜烯酮A在增强免疫力方面的新用途。本发明研究表明,姜烯酮A不仅能够提高白细胞介素2、免疫球蛋白、溶菌酶、黄嘌呤氧化酶的表达水平,显著改善机体的免疫功能,没有明显的副作用,而且能够增加机体的脾脏系数和胸腺系数,对免疫器官具有保护作用,说明姜烯酮A能够用于制备和/或作为增强免疫力产品方面。本发明还为增强免疫力药物的开发提供了一种新的治疗药物。
附图说明
图1为姜烯酮A对环磷酰胺诱导小鼠免疫功能低下炎性细胞因子及生化指标检测的影响(x±sd,n=8),图1A为姜烯酮A对IL-2表达水平的影响,图1B为姜烯酮A对IgG表达水平的影响,图1C为姜烯酮A对LZM表达水平的影响,图1D为姜烯酮A对XOD表达水平的影响。
图2为姜烯酮A对免疫抑制小鼠脏器系数的影响(x±sd,n=8),图2A为姜烯酮A对脾脏系数的影响,图2B为姜烯酮A对胸腺系数的影响。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
除非特别说明,以下实施例所用试剂和材料均为市购。
实施例1姜烯酮A增强免疫力的性能评价
1.实验动物:SPF级,雄性BALB/c小鼠(6-8周龄,18~22g),购买于广州中医药大学实验动物中心,许可证号:SYXK(粤)2018-0085。动物饲养于广州中医药大学实验动物中心SPF级实验动物房,动物饲养条件为:温度(20~25℃),湿度(65~70%),12h光照明暗交替,饲养时,动物给予标准的饲料和自由饮用无菌蒸馏水,每隔一天更换新的垫料。
2.实验方法:将雄性BALB/c小鼠按照体重随机分为5组,分别为:正常对照组、环磷酰胺模型组、环磷酰胺+姜烯酮A低剂量组(5mg/kg)、环磷酰胺+姜烯酮A中剂量组(10mg/kg)、环磷酰胺+姜烯酮A高剂量组(20mg/kg),每组10只。正常对照组每天腹腔注射生理盐水,环磷酰胺模型组每天腹腔注射30mg/kg,姜烯酮A组每天腹腔注射30mg/kg环磷酰胺,并且给予相应的药物进行干预治疗,连续给药造模7天,每天记录动物体重变化;实验结束后,处理动物,检测免疫相关指标。
a.炎性细胞因子及生化指标检测:实验结束后,动物麻醉后,经眼眶取血,分离血清,按照试剂盒的说明书,分别检测白细胞介素2(IL-2),免疫球蛋白(IgG)、溶菌酶(LZM)、黄嘌呤氧化酶(XOD)的表达水平。
b.计算脏器指数:采血后,小鼠经颈椎脱臼处死,解剖,采取脾脏和胸腺并称重,计算免疫器官的脏器系数。
结果分析:
(1)姜烯酮A对环磷酰胺诱导小鼠免疫功能低下炎性细胞因子及生化指标检测的影响(x±sd,n=8)如图1所示。
由图1A可知,与正常对照组比较,环磷酰胺模型组小鼠的IL-2的表达水平极显著降低(P<0.01);而给予姜烯酮A后,IL-2的表达水平随着姜烯酮A剂量的升高而增高。与环磷酰胺模型组比较,环磷酰胺+姜烯酮A高剂量组小鼠血清中的IL-2的表达水平显著增高(P<0.05);由图1B可知,与正常对照组比较,环磷酰胺模型组小鼠的IgG的表达水平极显著降低(P<0.01),而给予姜烯酮A后,IgG的表达水平随着姜烯酮A剂量的升高而增高。与环磷酰胺模型组比较,环磷酰胺+姜烯酮A中、高剂量组小鼠血清中的IgG的表达水平显著增高(P<0.05);由图1C可知,与正常对照组比较,环磷酰胺模型组小鼠的LZM的表达水平极显著降低(P<0.01),而给予姜烯酮A后,LZM的表达水平随着姜烯酮A剂量的升高而增高。与环磷酰胺模型组比较,环磷酰胺+姜烯酮A高剂量组小鼠血清中的LZM的表达水平显著增高(P<0.05);由图1D可知,与正常对照组比较,环磷酰胺模型组小鼠的XOD的表达水平极显著降低(P<0.01),而给予姜烯酮A后,XOD的表达水平随着姜烯酮A剂量的升高而增高。与环磷酰胺模型组比较,其中,环磷酰胺+姜烯酮A中剂量组小鼠血清中的XOD的表达水平显著增高(P<0.05),环磷酰胺+姜烯酮A高剂量组小鼠血清中的XOD的表达水平极显著增高(P<0.01)。上述结果表明,姜烯酮A能够通过升高免疫抑制小鼠中的细胞因子表达水平而改善其免疫功能。
(2)姜烯酮A对免疫抑制小鼠脏器系数的影响(x±sd,n=8)如图2所示。由图2A可知,与正常对照组比较,环磷酰胺模型组脾脏系数显著降低(P<0.01),差异具有统计学意义;而给予姜烯酮A后,小鼠脾脏系数随着姜烯酮A剂量的升高而增加。其中,环磷酰胺+姜烯酮A中剂量组的脾脏系数显著增加(P<0.05),环磷酰胺+姜烯酮A高剂量组的脾脏系数极显著增加(P<0.01);由图2B可知,与正常对照组比较,环磷酰胺模型组胸腺系数显著降低(P<0.01),差异具有统计学意义;而给予姜烯酮A后,小鼠胸腺系数随着姜烯酮A剂量的升高而增加。其中,环磷酰胺+姜烯酮A中、高剂量组的胸腺系数显著增加(P<0.05)。上述结果表明,姜烯酮A能够保护免疫低下模型小鼠的免疫器官,从而对小鼠的免疫力具有保护作用,即姜烯酮A能够增强免疫功能低下模型小鼠的免疫力。
Claims (8)
1.姜烯酮A作为唯一活性成分在制备增强机体免疫力的药物中的应用。
2.根据权利要求1所述的应用,其特征在于,姜烯酮A通过增高白细胞介素2含量增强机体免疫力。
3.根据权利要求1所述的应用,其特征在于,姜烯酮A通过增高免疫球蛋白含量增强机体免疫力。
4.根据权利要求1所述的应用,其特征在于,姜烯酮A通过增高溶菌酶含量增强机体免疫力。
5.根据权利要求1所述的应用,其特征在于,姜烯酮A通过增高黄嘌呤氧化酶含量增强机体免疫力。
6.根据权利要求1所述的应用,其特征在于,姜烯酮A通过保护机体免疫器官增强机体免疫力。
7.根据权利要求6所述应用,其特征在于,姜烯酮A通过增加脾脏系数保护机体免疫器官。
8.根据权利要求6所述应用,其特征在于,姜烯酮A通过增加胸腺系数保护机体免疫器官。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110536050.1A CN113244204B (zh) | 2021-05-17 | 2021-05-17 | 姜烯酮a在制备和/或作为增强机体免疫力产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110536050.1A CN113244204B (zh) | 2021-05-17 | 2021-05-17 | 姜烯酮a在制备和/或作为增强机体免疫力产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113244204A CN113244204A (zh) | 2021-08-13 |
CN113244204B true CN113244204B (zh) | 2023-04-11 |
Family
ID=77182383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110536050.1A Active CN113244204B (zh) | 2021-05-17 | 2021-05-17 | 姜烯酮a在制备和/或作为增强机体免疫力产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113244204B (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012051811A (ja) * | 2010-08-31 | 2012-03-15 | House Foods Corp | 免疫増強剤 |
KR101413528B1 (ko) * | 2011-02-23 | 2014-07-02 | 울산대학교 산학협력단 | 6―진저롤을 포함하는 면역 증강용 조성물 |
KR20130094553A (ko) * | 2012-02-16 | 2013-08-26 | 서울대학교산학협력단 | 진저레논 에이를 포함하는 암 예방용 식품 조성물, 암 치료용 약학조성물 및 암 치료용 동물용 의약품 |
CN111467327B (zh) * | 2020-04-27 | 2022-03-08 | 广州中医药大学(广州中医药研究院) | 姜烯酮a在制备防治结肠炎药物方面的应用 |
-
2021
- 2021-05-17 CN CN202110536050.1A patent/CN113244204B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113244204A (zh) | 2021-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10537600B2 (en) | Traditional Chinese medicine combination for regulating immune function and preparation method therefor | |
AU749922B2 (en) | A medicament for treating recurrent ulcer of mouth and Behcet's syndrome | |
CN1985922B (zh) | 一种治疗感冒的药物组合物及其制备方法 | |
CN113995788B (zh) | 一种保肝、护肝的组合物及其制备工艺 | |
CN101856384B (zh) | 一种护肝组合物 | |
CN109394809A (zh) | 一种提高免疫力的中药组合物及其制备方法和应用 | |
CN108813610A (zh) | 一种用于提高免疫力的雪莲组合物及其应用 | |
CN113244204B (zh) | 姜烯酮a在制备和/或作为增强机体免疫力产品中的应用 | |
CN114470042B (zh) | 一种防治动物肝损伤的组合物及其制备方法和用途 | |
CN101856415B (zh) | 治疗鸡呼吸道传染病的中草药口服液 | |
CN103142766B (zh) | 一种防治兔球虫病的药物 | |
CN100448472C (zh) | 一种治疗肺结核的中药制剂 | |
CN102188622A (zh) | 一种治疗抽动障碍疾病的有效药物和速效药物 | |
CN105343503B (zh) | 一种治疗咽喉炎的药物组合物及其应用 | |
CN109758559A (zh) | 一种治疗慢性疲劳综合征的中药组合物及其制备方法和应用 | |
CN1302798C (zh) | 用于治疗与预防辐射线损伤的药物 | |
CN100335098C (zh) | 一种治疗胃病的药物 | |
Du et al. | Experimental study on acute toxicity of Lucao Wenban granules | |
CN1273173C (zh) | 用于治疗与预防辐射线损伤药物的用途 | |
CN1454623A (zh) | 一种治疗咽喉疾病的中药 | |
CN1245204C (zh) | 一种治疗急性咽炎的药物及其制备方法 | |
CN115414428A (zh) | 一种提高鸡免疫力的中药组方及其应用 | |
Rakhimova | Improvement of Methods for Correction of Clinical and Immunological Disorders in Comorbid State of Chronic Inflammations after COVID-19 | |
CN106138680B (zh) | 一种具有抗氧化功能的中药组合物 | |
CN117919225A (zh) | 一种抗辐射损伤的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |